» Articles » PMID: 34295920

Selective Neuron Vulnerability in Common and Rare Diseases-Mitochondria in the Focus

Overview
Specialty Biology
Date 2021 Jul 23
PMID 34295920
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial dysfunction is a central feature of neurodegeneration within the central and peripheral nervous system, highlighting a strong dependence on proper mitochondrial function of neurons with especially high energy consumptions. The fitness of mitochondria critically depends on preservation of distinct processes, including the maintenance of their own genome, mitochondrial dynamics, quality control, and Ca handling. These processes appear to be differently affected in common neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as well as in rare neurological disorders, including Huntington's disease, Amyotrophic Lateral Sclerosis and peripheral neuropathies. Strikingly, particular neuron populations of different morphology and function perish in these diseases, suggesting that cell-type specific factors contribute to the vulnerability to distinct mitochondrial defects. Here we review the disruption of mitochondrial processes in common as well as in rare neurological disorders and its impact on selective neurodegeneration. Understanding discrepancies and commonalities regarding mitochondrial dysfunction as well as individual neuronal demands will help to design new targets and to make use of already established treatments in order to improve treatment of these diseases.

Citing Articles

Amyotrophic lateral sclerosis represents corticomotoneuronal system failure.

Eisen A, Vucic S, Kiernan M Muscle Nerve. 2024; 71(4):499-511.

PMID: 39511939 PMC: 11887532. DOI: 10.1002/mus.28290.


Mitochondrial DNA Instability Supersedes Parkin Mutations in Driving Mitochondrial Proteomic Alterations and Functional Deficits in Polg Mutator Mice.

Trease A, Totusek S, Lichter E, Stauch K, Fox H Int J Mol Sci. 2024; 25(12).

PMID: 38928146 PMC: 11203920. DOI: 10.3390/ijms25126441.


Mitochondria and the eye-manifestations of mitochondrial diseases and their management.

Chen B, Harvey J, Gilhooley M, Jurkute N, Yu-Wai-Man P Eye (Lond). 2023; 37(12):2416-2425.

PMID: 37185957 PMC: 10397317. DOI: 10.1038/s41433-023-02523-x.


Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer's Disease Progression.

Andronie-Cioara F, Ardelean A, Nistor-Cseppento C, Jurcau A, Jurcau M, Pascalau N Int J Mol Sci. 2023; 24(3).

PMID: 36768235 PMC: 9915182. DOI: 10.3390/ijms24031869.


Blood RNA transcripts reveal similar and differential alterations in fundamental cellular processes in Alzheimer's disease and other neurodegenerative diseases.

Huseby C, Delvaux E, Brokaw D, Coleman P Alzheimers Dement. 2022; 19(6):2618-2632.

PMID: 36541444 PMC: 11633037. DOI: 10.1002/alz.12880.


References
1.
Stoica R, De Vos K, Paillusson S, Mueller S, Sancho R, Lau K . ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat Commun. 2014; 5:3996. PMC: 4046113. DOI: 10.1038/ncomms4996. View

2.
Pozo Devoto V, Dimopoulos N, Alloatti M, Pardi M, Saez T, Otero M . αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson's disease. Sci Rep. 2017; 7(1):5042. PMC: 5506004. DOI: 10.1038/s41598-017-05334-9. View

3.
Deng Z, Lim J, Wang Q, Purtell K, Wu S, Palomo G . ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy. 2019; 16(5):917-931. PMC: 7144840. DOI: 10.1080/15548627.2019.1644076. View

4.
. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Ann Intern Med. 2020; 172(9):591-598. PMC: 7465126. DOI: 10.7326/M19-2534. View

5.
Halliday G, McRitchie D, MacDonald V, Double K, Trent R, McCusker E . Regional specificity of brain atrophy in Huntington's disease. Exp Neurol. 1999; 154(2):663-72. DOI: 10.1006/exnr.1998.6919. View